InsidersTradesSigma
Total declarations
Company
▲ Purchases (28 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by CROCKER GARY L, Executive. Insider active across 1 company, notably Merrimack Pharmaceuticals INC. Aggregated, 28 filings have been published. Split: 28 buys · 0 sell. Total volume traded: €437k. History available since 11 January 2022. The latest transaction was filed on 9 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations28 total
4,452 shares@ US$5.14784.9% of flowCommon StockSEC:0000899243-22-022153:0
Ideal exit: 6 Mar 2023 (T+270)
300 shares@ US$5.050.3% of flowCommon StockSEC:0000899243-22-021612:0
Ideal exit: 4 Mar 2023 (T+270)
2,323 shares@ US$5.08692.5% of flowCommon StockSEC:0000899243-22-019682:0
Ideal exit: 18 Feb 2023 (T+270)
512 shares@ US$5.04280.6% of flowCommon StockSEC:0000899243-22-019200:0
Ideal exit: 13 Feb 2023 (T+270)
225 shares@ US$5.09560.2% of flowCommon StockSEC:0000899243-22-018778:0
Ideal exit: 11 Feb 2023 (T+270)
2,471 shares@ US$5.04092.7% of flowCommon StockSEC:0000899243-22-018126:0
Ideal exit: 6 Feb 2023 (T+270)
5,000 shares@ US$6.00026.3% of flowCommon StockSEC:0000899243-22-015556:0
Ideal exit: 16 Jan 2023 (T+270)
161 shares@ US$6.200.2% of flowCommon StockSEC:0000899243-22-013091:0
Ideal exit: 25 Dec 2022 (T+270)
5,000 shares@ US$6.16436.4% of flowCommon StockSEC:0000899243-22-012692:0
Ideal exit: 23 Dec 2022 (T+270)
400 shares@ US$6.11380.5% of flowCommon StockSEC:0000899243-22-012077:0
Ideal exit: 17 Dec 2022 (T+270)
4,649 shares@ US$6.14236.0% of flowCommon StockSEC:0000899243-22-011381:0
Ideal exit: 10 Dec 2022 (T+270)
5,000 shares@ US$6.08136.3% of flowCommon StockSEC:0000899243-22-011037:0
Ideal exit: 6 Dec 2022 (T+270)
3,351 shares@ US$5.95934.0% of flowCommon StockSEC:0000899243-22-007378:0
Ideal exit: 15 Nov 2022 (T+270)
7,945 shares@ US$6.19659.9% of flowCommon StockSEC:0000899243-22-007005:0
Ideal exit: 13 Nov 2022 (T+270)
7,945 shares@ US$6.196535.0% of flowCommon StockSEC:0000899243-22-007005
Ideal exit: 13 Nov 2022 (T+270)
1,800 shares@ US$5.95762.2% of flowCommon StockSEC:0000899243-22-006627:0
Ideal exit: 11 Nov 2022 (T+270)
673 shares@ US$4.600.6% of flowCommon StockSEC:0000899243-22-003632:0
Ideal exit: 24 Oct 2022 (T+270)
673 shares@ US$4.602.2% of flowCommon StockSEC:0000899243-22-003632
Ideal exit: 24 Oct 2022 (T+270)
3,100 shares@ US$4.55522.9% of flowCommon StockSEC:0000899243-22-003422:0
Ideal exit: 23 Oct 2022 (T+270)
3,100 shares@ US$4.555210.1% of flowCommon StockSEC:0000899243-22-003422
Ideal exit: 23 Oct 2022 (T+270)
2,000 shares@ US$4.65481.9% of flowCommon StockSEC:0000899243-22-003136:0
Ideal exit: 18 Oct 2022 (T+270)
2,000 shares@ US$4.65486.6% of flowCommon StockSEC:0000899243-22-003136
Ideal exit: 18 Oct 2022 (T+270)
5,000 shares@ US$4.537916.1% of flowCommon StockSEC:0000899243-22-002634
Ideal exit: 15 Oct 2022 (T+270)
5,000 shares@ US$4.53794.6% of flowCommon StockSEC:0000899243-22-002634:0
Ideal exit: 15 Oct 2022 (T+270)
5,000 shares@ US$4.424115.6% of flowCommon StockSEC:0000899243-22-002118
Ideal exit: 10 Oct 2022 (T+270)
25 of 28 declarations
About CROCKER GARY L
Gary L. Crocker is an insider at Merrimack Pharmaceuticals Inc.
